Alvotech (NASDAQ:ALVO) Releases Quarterly Earnings Results, Misses Expectations By $0.19 EPS

Alvotech (NASDAQ:ALVO) posted its earnings results on Wednesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.19), Zacks reports.

Alvotech Stock Performance

Shares of ALVO traded up $0.04 during mid-day trading on Wednesday, hitting $4.92. The company’s stock had a trading volume of 783,647 shares, compared to its average volume of 766,411. The stock’s 50-day moving average is $5.28 and its two-hundred day moving average is $4.21. The firm has a market capitalization of $1.48 billion, a PE ratio of -8.07 and a beta of 0.24. Alvotech has a one year low of $2.94 and a one year high of $6.53.

Recent Alvotech Headlines

Investors following ALVO have been watching these headlines:

• Positive Sentiment: Jefferies initiated coverage with a Buy rating and a $9 price target, which may support sentiment toward the shares. Jefferies initiates Alvotech at Buy
• Neutral Sentiment: Alvotech maintained 2026 revenue guidance of $650 million–$700 million and EBITDA guidance of $180 million–$220 million. The revenue range is broadly in line with the $652.5 million consensus estimate, though management expects results toward the lower end.
• Negative Sentiment: Nine-month adjusted revenue declined 23% year over year to $323.4 million, and gross margin contracted to 54% from 59%. Cash fell to $61.5 million from $172.4 million at year-end 2025; operating cash outflow was $205.6 million, adding to liquidity concerns. Alvotech financial results and business update

Wall Street Analysts Forecast Growth

ALVO has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday. Evercore initiated coverage on shares of Alvotech in a report on Friday, August 14th. They set an “outperform” rating for the company. Jefferies Financial Group assumed coverage on Alvotech in a research report on Tuesday. They issued a “buy” rating and a $9.00 price target on the stock. Weiss Ratings upgraded Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Finally, Zacks Research cut Alvotech from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Five analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $8.40.

Alvotech Company Profile

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.